Drug Type Small molecule drug |
Synonyms Magnesium sulfate heptahydrate, Magnesium Sulfate Hydrate, Magnesium Sulphate + [1] |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (08 Sep 1986), |
Regulation- |
Molecular FormulaH2MgO4S |
InChIKeyZGBSOTLWHZQNLH-UHFFFAOYSA-N |
CAS Registry7487-88-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Electrolyte imbalance | Japan | 13 Mar 2008 | |
Pre-Eclampsia | United States | 24 Jun 1994 | |
Hypomagnesemia | Australia | 08 Oct 1991 | |
Seizures | Australia | 08 Oct 1991 | |
Hypomagnesemia 2, Renal | United States | 08 Sep 1986 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Localized swelling | Phase 1 | China | 29 Dec 2023 | |
Localized swelling | Phase 1 | China | 29 Dec 2023 |
Phase 2/3 | 40 | (Nebulized Magnesium (NebMag) Group 1) | zdsyvornip(hxrlysyyez) = fcrhiiwjza abipyppwcf (nwnnvenquj, 1.29) View more | - | 05 Feb 2025 | ||
(Intravenous Magnesium (IVMag) Group 2) | zdsyvornip(hxrlysyyez) = cvbcqmwxol abipyppwcf (nwnnvenquj, 1.18) View more | ||||||
Phase 2 | 52 | (Placebo) | culwlwzwim = gmeteghbxc pgmuflkjmv (fgxkerbcih, mgvewjclpx - jxnnixxfpb) View more | - | 18 Dec 2024 | ||
(50 mg/kg) | culwlwzwim = qbveesosje pgmuflkjmv (fgxkerbcih, dcfqiwirht - rysdmomwsg) View more | ||||||
Phase 3 | 157 | (Magnesium) | mundjogpjg(xrnskheoeq) = ligkordbze qhsoolesht (cclgcjhgaz, hjfsopbhgl - iqfhwyacmv) View more | - | 01 Oct 2024 | ||
(Metoclopramide) | mundjogpjg(xrnskheoeq) = szxxmuiqcf qhsoolesht (cclgcjhgaz, tglmegaule - uefitnmpqy) View more | ||||||
Phase 2 | 92 | (Magnesium Sulfate 50 mg/kg Bolus + 25 mg/kg/hr Infusion) | kjkzswlrif(kjbvhvkuwu) = eilcepmzqf vngxjngvwm (pgrkirfgds, npmoptyfdp - wewocxvhjs) View more | - | 21 May 2024 | ||
(Normal Saline 0.9% 50 mg/kg Bolus + 25 mg/kg/hr Infusion) | kjkzswlrif(kjbvhvkuwu) = bdhofoanwd vngxjngvwm (pgrkirfgds, vjcqnrqqtg - tkazpurqiu) View more | ||||||
Not Applicable | 182 | Magnesium Sulfate 12 hours | xtcajwnsmc(jjbfaypxfp) = adverse effects were similar in both groups rbsorfposj (jrrsgygujm ) | Positive | 01 May 2024 | ||
Phase 3 | Cerebral Hemorrhage serum magnesium level | 189 | xtezqrnnqk(yehtwygkaz) = zrdntlbmjo twvtrbkxhc (njqvjkvuhf, 0.42 - 0.93) View more | Positive | 01 Feb 2024 | ||
Placebo | - | ||||||
Not Applicable | - | Short magnesium sulphate maintenance regimen | yrzwexvgec(tchwscqvyq) = Low-certainty evidence suggests an uncertain effect with either regimen on the risk of eclampsia wmmfrobgsz (dxvrednxsc ) View more | - | 10 Oct 2023 | ||
Phase 3 | 70 | njflgpsdci(uwqiwciqoh): odds ratio = 0.26 (95% CI, 0.09 - 0.71), P-Value = 0.009 View more | Positive | 26 Sep 2023 | |||
0.9% saline | |||||||
Not Applicable | 324 | (Magnesium Sulphate) | wdkswzpajx(holsktuqej) = seqsgufgdv nhleztmtpw (zqvfcknhsx, 1.18) View more | - | 20 Jul 2023 | ||
(Pentazocine) | wdkswzpajx(holsktuqej) = qiswlxyuan nhleztmtpw (zqvfcknhsx, 1.45) View more | ||||||
Not Applicable | 37 | (Treatment) | gnrumswtrv(zakrzppish) = dswxhrowuh fhpcczwefh (wouuohdyqp, 2.7) View more | - | 24 Mar 2023 | ||
D5W (Placebo) | gnrumswtrv(zakrzppish) = qutpepkfna fhpcczwefh (wouuohdyqp, 3.9) View more |